Table 1 Overview of basic characteristics of renal, heart failure and cardiovascular outcome studies completed in 2019
From: Report from the 5th cardiovascular outcome trial (CVOT) summit
| Study name | Study status | Drug | Drug class | Intervention | Primary outcome | N | Follow up [years] | Start and end date | Clinicaltrials.gov ID |
|---|---|---|---|---|---|---|---|---|---|
| CAROLINA [18] | Completed | Linagliptin | DPP-4 inhibitor | Linagliptin 5 mg once daily vs. Glimepiride 1-4 mg | CV-death, non-fatal MI, non-fatal stroke | 6.042 | 6.3 | 11.2010–08.2018 | NCT01243424 |
| PIONEER-6 [20] | Completed | Semaglutide oral | GLP-1 receptor agonist | Semaglutide oral 14 mg once daily vs. placebo | Death from CV causes (including undetermined causes of death), non-fatal MI, non-fatal stroke | 3.183 | 1.3 | 01.2017–09.2018 | NCT02692716 |
| REWIND [19] | Completed | Dulaglutide | GLP-1 receptor agonist | Dulaglutide 1.5 mg weekly vs. placebo | Non-fatal MI, non-fatal stroke, death from CV causes or unknown causes | 9.901 | 5.4 | 07.2011–08.2018 | NCT01394952 |
| CREDENCE [21] | Completed | Canagliflozin | SGLT-2 inhibitor | Canagliflozin 100 mg once daily vs. placebo | End-stage kidney disease, sustained doubling of serum creatinine level, death from renal or CV disease | 4.401 | 2.6 | 02.2014–10.2018 | NCT02065791 |
| DAPA-HF [22] | Completed | Dapagliflozin | SGLT-2 inhibitor | Dapagliflozin 10 mg once daily vs. placebo | Worsening heart failure or death from CV causes | 4.744 | 1.5 | 02.2017–07.2019 | NCT03036124 |